The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study
<h3>Background</h3><p dir="ltr">Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513518693253120 |
|---|---|
| author | Mohsen Abbasi-Kangevari (9714440) |
| author2 | Sahar Saeedi Moghaddam (7581314) Seyyed-Hadi Ghamari (10116361) Mohammadreza Azangou-Khyavy (12229454) Mohammad-Reza Malekpour (10116358) Negar Rezaei (6208406) Nazila Rezaei (6208433) Ali-Asghar Kolahi (11168677) Erfan Amini (13779805) Ali H. Mokdad (7495784) Hamidreza Jamshidi (4066222) Mohsen Naghavi (34491) Bagher Larijani (96114) Farshad Farzadfar (439490) GBD 2019 NAME Prostate Cancer Collaborators (13779802) Hanadi Al Hamad (11553634) Brijesh Sathian (479264) Mowafa Househ (9154124) |
| author2_role | author author author author author author author author author author author author author author author author author |
| author_facet | Mohsen Abbasi-Kangevari (9714440) Sahar Saeedi Moghaddam (7581314) Seyyed-Hadi Ghamari (10116361) Mohammadreza Azangou-Khyavy (12229454) Mohammad-Reza Malekpour (10116358) Negar Rezaei (6208406) Nazila Rezaei (6208433) Ali-Asghar Kolahi (11168677) Erfan Amini (13779805) Ali H. Mokdad (7495784) Hamidreza Jamshidi (4066222) Mohsen Naghavi (34491) Bagher Larijani (96114) Farshad Farzadfar (439490) GBD 2019 NAME Prostate Cancer Collaborators (13779802) Hanadi Al Hamad (11553634) Brijesh Sathian (479264) Mowafa Househ (9154124) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohsen Abbasi-Kangevari (9714440) Sahar Saeedi Moghaddam (7581314) Seyyed-Hadi Ghamari (10116361) Mohammadreza Azangou-Khyavy (12229454) Mohammad-Reza Malekpour (10116358) Negar Rezaei (6208406) Nazila Rezaei (6208433) Ali-Asghar Kolahi (11168677) Erfan Amini (13779805) Ali H. Mokdad (7495784) Hamidreza Jamshidi (4066222) Mohsen Naghavi (34491) Bagher Larijani (96114) Farshad Farzadfar (439490) GBD 2019 NAME Prostate Cancer Collaborators (13779802) Hanadi Al Hamad (11553634) Brijesh Sathian (479264) Mowafa Househ (9154124) |
| dc.date.none.fl_str_mv | 2022-09-13T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/fonc.2022.961086 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_burden_of_prostate_cancer_in_North_Africa_and_Middle_East_1990_2019_Findings_from_the_global_burden_of_disease_study/25611645 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis Health sciences Epidemiology cancer global burden of disease incidence mortality prostate-specific antigen prostatic neoplasms |
| dc.title.none.fl_str_mv | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019.</p><h3>Methods</h3><p dir="ltr">This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment.</p><h3>Results</h3><p dir="ltr">The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively.</p><h3>Conclusions</h3><p dir="ltr">The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Oncology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fonc.2022.961086" target="_blank">https://dx.doi.org/10.3389/fonc.2022.961086</a></p><p dir="ltr">Additional institutions affiliated with: WHO Collaborating Center for Healthy Ageing and Dementia - HMC</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_876e988d60e288843aae2abd8de06da5 |
| identifier_str_mv | 10.3389/fonc.2022.961086 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25611645 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease studyMohsen Abbasi-Kangevari (9714440)Sahar Saeedi Moghaddam (7581314)Seyyed-Hadi Ghamari (10116361)Mohammadreza Azangou-Khyavy (12229454)Mohammad-Reza Malekpour (10116358)Negar Rezaei (6208406)Nazila Rezaei (6208433)Ali-Asghar Kolahi (11168677)Erfan Amini (13779805)Ali H. Mokdad (7495784)Hamidreza Jamshidi (4066222)Mohsen Naghavi (34491)Bagher Larijani (96114)Farshad Farzadfar (439490)GBD 2019 NAME Prostate Cancer Collaborators (13779802)Hanadi Al Hamad (11553634)Brijesh Sathian (479264)Mowafa Househ (9154124)Biomedical and clinical sciencesOncology and carcinogenesisHealth sciencesEpidemiologycancerglobal burden of diseaseincidencemortalityprostate-specific antigenprostatic neoplasms<h3>Background</h3><p dir="ltr">Prostate cancer (PCa) is the second most prevalent cancer among men worldwide. This study presents estimates of PCa prevalence, incidence, death, years-of-life-lost (YLLs), years-lived-with-disability (YLDs), disability-adjusted-life-years (DALYs), and the burden attributable to smoking during 1990-2019 in North Africa and Middle East using data of Global Burden of Diseases (GBD) Study 2019.</p><h3>Methods</h3><p dir="ltr">This study is a part of GBD 2019. Using vital registration and cancer registry data, the estimates on PCa burden were modeled. Risk factor analysis was performed through the six-step conceptual framework of Comparative Risk Assessment.</p><h3>Results</h3><p dir="ltr">The age-standardized rates (95% UI) of PCa incidence, prevalence, and death in 2019 were 23.7 (18.5-27.9), 161.1 (126.6-187.6), and 11.7 (9.4-13.9) per 100,000 population. While PCa incidence and prevalence increased by 77% and 144% during 1990-2019, respectively, the death rate stagnated. Of the 397% increase in PCa new cases, 234% was due to a rise in the age-specific incidence rate, 79% due to population growth, and 84% due to population aging. The YLLs, YLDs, and DALYs of PCa increased by 2% (-11.8-23.1), 108% (75.5-155.1), and 6% (-8.9-28.1). The death rate and DALYs rate attributable to smoking have decreased 12% and 10%, respectively. The DALYs rate attributable to smoking was 37.4 (15.9-67.8) in Lebanon and 5.9 (2.5-10.6) in Saudi Arabia, which were the highest and lowest in the region, respectively.</p><h3>Conclusions</h3><p dir="ltr">The PCa incidence and prevalence rates increased during 1990-2019; however, the death rate stagnated. The increase in the incidence was mostly due to the rise in the age-specific incidence rate, rather than population growth or aging. The burden of PCa attributable to smoking has decreased in the past 30 years.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Oncology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fonc.2022.961086" target="_blank">https://dx.doi.org/10.3389/fonc.2022.961086</a></p><p dir="ltr">Additional institutions affiliated with: WHO Collaborating Center for Healthy Ageing and Dementia - HMC</p>2022-09-13T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fonc.2022.961086https://figshare.com/articles/journal_contribution/The_burden_of_prostate_cancer_in_North_Africa_and_Middle_East_1990_2019_Findings_from_the_global_burden_of_disease_study/25611645CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/256116452022-09-13T03:00:00Z |
| spellingShingle | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study Mohsen Abbasi-Kangevari (9714440) Biomedical and clinical sciences Oncology and carcinogenesis Health sciences Epidemiology cancer global burden of disease incidence mortality prostate-specific antigen prostatic neoplasms |
| status_str | publishedVersion |
| title | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| title_full | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| title_fullStr | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| title_full_unstemmed | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| title_short | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| title_sort | The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis Health sciences Epidemiology cancer global burden of disease incidence mortality prostate-specific antigen prostatic neoplasms |